Patient Protection and Affordable Care Act (PPACA) implementation issues; Budget Control Act of 2011; Sustainable Growth Rate reform; Medicare reimbursement and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Patient Protection and Affordable Care Act (PPACA) implementation issues; Medicare reimbursement and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Patient Protection and Affordable Care Act (PPACA) implementation issues; Coverage and pricing policies for molecular diagnostic cancer tests; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Sustainable Growth Rate reform; Clinical lab and physician fee schedule reforms and beneficiary cost sharing proposals; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Duration: March 21, 2011
to
June 20, 2014
General Issues: Medical/Disease Research/Clinical Labs , Health Issues , Insurance , Medicare/Medicaid
Spending: about $994,448 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: House of Representatives, U.S. Senate, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Amy Jensen Cunniffe
Special Assistant to the President for Legislative Affairs
Assistant to the Speaker of the House for Policy
Special Asst. to the President for Legislative Affair
Asst. to Speaker of the House for Policy
Asst. to the Speaker of the House for Policy
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2014
Caris Science, Inc. in-house lobbying effort was terminated on July 21, 2014
Original Filing: 300667438.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Budget Control Act of 2011; Sustainable Growth Rate reform; Medicare reimbursement and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Medicare reimbursement and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Coverage and pricing policies for molecular diagnostic cancer tests; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Sustainable Growth Rate reform; Clinical lab and physician fee schedule reforms and beneficiary cost sharing proposals; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2014
In Q1, Caris Science, Inc. had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300645719.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Budget Control Act of 2011; Sustainable Growth Rate reform; Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2015 Medicare funding proposals; advanced molecular diagnostic policy; lab and pathology coverage and payment issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2015 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Coverage and pricing policies for molecular diagnostic cancer tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Sustainable Growth Rate reform; Clinical lab and physician fee schedule reforms and beneficiary cost sharing proposals; President Obama's FY2015 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2013
In Q4, Caris Science, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2014.
Original Filing: 300621428.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Sustainable Growth Rate reform; Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Coverage and pricing policies for molecular diagnostic cancer tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Sustainable Growth Rate reform; Clinical lab and physician fee schedule reforms and beneficiary cost sharing proposals; President Obama's FY2014 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2013
In Q3, Caris Science, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300605155.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Budget Control Act of 2011; Sustainable Growth Rate reform; Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues; Coverage and pricing policies for molecular diagnostic cancer tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Sustainable Growth Rate reform; Clinical lab and physician fee schedule reforms and beneficiary cost sharing proposals; President Obama's FY2014 Medicare funding proposals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2013
In Q2, Caris Science, Inc. had in-house lobbyists. The report was filed on July 22, 2013.
Original Filing: 300581642.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011, and Medicare Clinical Laboratory Fee Schedule reimbursement issues including pricing for and coverage of molecular diagnostic tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011, and Medicare Clinical Laboratory Fee Schedule reimbursement issues including pricing for and coverage of molecular diagnostic tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
1st Quarter, 2013
In Q1, Caris Science, Inc. had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300559450.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
4th Quarter, 2012
In Q4, Caris Science, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300538108.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
3rd Quarter, 2012
In Q3, Caris Science, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2012.
Original Filing: 300514938.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform, Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
Fee schedule placement of genomic and genetic tests, Proposed CY2012 Medicare Physician Fee Schedule Rule (CMS-1590-P).Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
2nd Quarter, 2012
Caris Science, Inc. amended a lobbying report for in-house lobbying in Q22012 on July 27, 2012
Original Filing: 300500556.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
S 3187 the FDA Safety and Innovation Act.Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
S 3187 the FDA Safety and Innovation Act.Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
2nd Quarter, 2012
In Q2, Caris Life Sciences, Ltd. d/b/a Caris Life Sciences had in-house lobbyists. The report was filed on July 20, 2012.
Original Filing: 300497628.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
S 3187 the FDA Safety and Innovation Act.Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Budget Control Act of 2011, Sustainable Growth Rate reform,
S 3187 the FDA Safety and Innovation Act.Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
1st Quarter, 2012
Caris Science, Inc. amended a lobbying report for in-house lobbying in Q12012 on July 27, 2012
Original Filing: 300500538.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Integrity in Medicare Self Referral for Lab & Pathology issues, Budget Control Act of 2011, Sustainable Growth Rate reform. Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Integrity in Medicare Self Referral for Lab & Pathology issues, Budget Control Act of 2011, Sustainable Growth Rate reform.Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
1st Quarter, 2012
In Q1, Caris Life Sciences, Ltd. d/b/a Caris Life Sciences had in-house lobbyists. The report was filed on April 19, 2012.
Original Filing: 300467754.xml
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Integrity in Medicare Self Referral for Lab & Pathology issues, Budget Control Act of 2011, Sustainable Growth Rate reform. Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patient Protection and Affordable Care Act (PPACA) implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Integrity in Medicare Self Referral for Lab & Pathology issues, Budget Control Act of 2011, Sustainable Growth Rate reform.Medicare funding and beneficiary cost-sharing for Clinical Lab Fee Schedule in HR 3630-The Middle Class Tax Relief & Job Creation Act of 2012 and HR 3765-The Temporary Payroll Tax Cut Continuation Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
4th Quarter, 2011
In Q4, Caris Life Sciences, Ltd. formerly known as Caris Life Sciences, Inc. had in-house lobbyists. The report was filed on Jan. 18, 2012.
Original Filing: 300440698.xml
Lobbying Issues
Reimbursement and cost sharing issues for lab-developed tests, PPACA implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Integrity in Medicare Self Referral for Lab & Pathology issues, Budget Control Act of 2011, HR 3765-Temporary Payroll Tax Cut Continuation Act of 2011, Sustainable Growth Rate reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Reimbursement and cost sharing issues for lab-developed tests, PPACA implementation issues, HR 2461- The Physician Pathology Continuity Act, HR 3207-Modernizing Lab Test Standards for Patients Act of 2011, Integrity in Medicare Self Referral for Lab & Pathology issues, Budget Control Act of 2011, HR 3765-Temporary Payroll Tax Cut Continuation Act of 2011, Sustainable Growth Rate reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
3rd Quarter, 2011
In Q3, Caris Life Sciences, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300422738.xml
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organization, Sustainable Growth Rate reform, pathology reimbursement issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
2nd Quarter, 2011
In Q2, Caris Life Sciences, Inc. had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300403855.xml
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organization, Sustainable Growth Rate reform, pathology reimbursement issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
1st Quarter, 2011
Caris Science, Inc. formerly known as Caris Life Sciences, Inc . filed a lobbying registration on July 26, 2012 for in-house lobbying efforts, effective March 21, 2011.
Original Filing: 300500534.xml
Issue(s) they said they’d lobby about: Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform .
1st Quarter, 2011
Caris Life Sciences, Inc. amended a lobbying report for in-house lobbying in Q12011 on July 20, 2011
Original Filing: 300403883.xml
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organization, Sustainable Growth Rate reform, pathology reimbursement issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Insurance Medicare/Medicaid
1st Quarter, 2011
In Q1, Caris Life Sciences, Inc. had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300373738.xml
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organization, Sustainable Growth Rate reform, pathology reimbursement issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP) Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Insurance Medicare/Medicaid
1st Quarter, 2011
Caris Life Sciences, Inc. filed a lobbying registration on March 21, 2011 for in-house lobbying efforts, effective March 21, 2011.
Original Filing: 300359103.xml
Issue(s) they said they’d lobby about: Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate